by Landex Pharma
GIP / GLP-1 / glucagon triple agonist. Supplied by Landex Pharma for laboratory research.
Coming soon
This compound is announced and not yet shipping. Ask a representative to be told as soon as it is available.
Already know the quantity? Add it to your message. Shipping and payment
Batch certificate of analysis available on request via Telegram or the contact form.
Retatrutide is a synthetic peptide that acts as an agonist at the GIP, GLP-1 and glucagon receptors. It is under clinical investigation, and published phase 2 data have examined body weight, glycaemic and liver-fat outcomes. Its triple-receptor pharmacology makes it a focus of comparative research against single and dual incretin agonists.
It is supplied here strictly for laboratory research. Retatrutide from Landex Pharma: formula C₂₂₁H₃₄₂N₄₆O₆₈, molecular weight 4731g/mol. This compound has been announced by the supplier and is not yet shipping.
Ask a representative to be told when it becomes available. Supplied by Landex Pharma. For in-vitro and laboratory research use only.
Not for human consumption, veterinary use or any therapeutic purpose.
Weight Loss & GLP-1
GLP-1 receptor agonist research is evolving rapidly beyond injectable semaglutide: oral formulations, triple agonists (GLP-1/GIP/glucagon), CNS-targeted analogs, and organ-protective applications. Research guide to the next-generation GLP-1 pipeline and the mechanistic frontiers being explored in 2025–2026.
6 min read
Peptides & Recovery
GLP-1 receptor agonists improve insulin resistance through multiple mechanisms beyond GLP-1R signaling — including hepatic gluconeogenesis suppression, adipose tissue remodeling, and GIP receptor co-stimulation. Advanced research guide to GLP-1 insulin sensitization pathways and experimental models.
5 min read
Weight Loss & GLP-1
Semaglutide, retatrutide, and tirzepatide represent three generations of incretin-based therapy with distinct receptor targets. Research comparison of mechanisms, clinical trial weight loss data, receptor pharmacology, and research applications for each compound class.
4 min read
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Must be handled by qualified professionals in a controlled laboratory setting. JuicedPharma makes no therapeutic or medical claims about this compound.
Hilma Biocare
Triple GIP/GLP-1/Glucagon agonist. Next-generation metabolic research compound.
98.5%· Janoshik
ZPHC
Retatrutide 10mg (5×2mg) lyophilized by ZPHC. Triple GIP/GLP-1/Glucagon agonist.
99%+· ZPHC
ZPHC
Retatrutide 15mg single vial by ZPHC. Starter dose for triple agonist research.
99%+· ZPHC
ZPHC
Retatrutide 20mg kit (5×4mg) by ZPHC. GIP/GLP-1/Glucagon triple agonist.
99%+· ZPHC
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer